Reducing cardiovascular outcomes with semaglutide: a metabolic route for a SELECT few

被引：1
|
作者：
Liuzzo, Giovanna [1 ,2 ]
Patrono, Carlo [1 ,3 ]
机构：
[1] Catholic Univ, Dept Cardiovasc & Pulm Sci, Sch Med, Largo F Vito 1, I-00168 Rome, Italy
[2] Fdn Policlin Univ A Gemelli IRCCS, Dept Cardiovasc Sci, Largo A Gemelli 8, I-00168 Rome, Italy
[3] Catholic Univ, Dept Pharmacol, Sch Med, Largo F Vito 1, I-00168 Rome, Italy
来源：
EUROPEAN HEART JOURNAL | 2024年 / 45卷 / 08期
关键词：
MORTALITY;
D O I：
10.1093/eurheartj/ehad823
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：570 / 571
页数：2
相关论文
共 50 条
  • [41] Cardiovascular outcomes for obesity and metabolic syndrome
    Vega, GL
    OBESITY RESEARCH, 2002, 10 : 27S - 32S
  • [42] Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
    McGuire, D. K.
    Marx, N.
    Mulvagh, S. L.
    Deanfield, J. E.
    Inzucchi, S. E.
    Pop-Busui, R.
    Mann, J. F. E.
    Emerson, S. S.
    Poulter, N. R.
    Engelmann, M. D. M.
    Ripa, M. S.
    Hovingh, G. K.
    Brown-Frandsen, K.
    Bain, S. C.
    Cavender, M. A.
    Gislum, M.
    David, J-P
    Buse, J. B.
    SOUL Study Group
    NEW ENGLAND JOURNAL OF MEDICINE, 2025,
  • [43] Weekly Journal Scan: SELECT renoprotective effects of semaglutide in non-diabetic, obese patients with cardiovascular disease
    Vergallo, Rocco
    Volpe, Massimo
    EUROPEAN HEART JOURNAL, 2024, 45 (44) : 4769 - 4771
  • [44] Implications of the CANVAS Study in Reducing Cardiovascular Outcomes
    Ameena Madan Paramasivan
    Archana Purushothaman
    Cyrus Desouza
    Current Diabetes Reports, 2018, 18
  • [45] Implications of the CANVAS Study in Reducing Cardiovascular Outcomes
    Paramasivan, Ameena Madan
    Purushothaman, Archana
    Desouza, Cyrus
    CURRENT DIABETES REPORTS, 2018, 18 (12)
  • [46] SELECT CARDIOVASCULAR AND METABOLIC RESPONSES OF DIABETIC RATS TO MODERATE EXERCISE TRAINING
    WEGNER, JA
    LUND, DD
    OVERTON, JM
    EDWARDS, JG
    ODA, RP
    TIPTON, CM
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 1987, 19 (05): : 497 - 503
  • [47] Lipid Metabolic Disorder Further reducing the Cardiovascular Risk
    Marx, Nikolaus
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2016, 141 (12) : 856 - 856
  • [48] Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide
    Verma, Subodh
    Fainberg, Udi
    Husain, Mansoor
    Rasmussen, Soren
    Ryden, Lars
    Ripa, Maria Sejersten
    Buse, John B.
    DIABETES OBESITY & METABOLISM, 2021, 23 (07): : 1677 - 1680
  • [49] Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity
    Verma, Subodh
    Emerson, Scott
    Plutzky, Jorge
    Kahn, Steven E.
    Stensen, Signe
    Weeke, Peter E.
    Musinga, Derrick
    Poirier, Paul
    Lingvay, Ildiko
    Lincoff, A. Michael
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2025, 85 (05) : 541 - 545
  • [50] The cost-effectiveness of semaglutide in reducing cardiovascular risk among people with overweight and obesity and existing cardiovascular disease, but without diabetes
    Zomer, Ella
    Zhou, Jennifer
    Nelson, Adam J.
    Sumithran, Priya
    Nanayakkara, Shane
    Ball, Jocasta
    Kaye, David
    Liew, Danny
    Nicholls, Stephen J.
    Stub, Dion
    Zoungas, Sophia
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2024,
12345